@inbook{74f4027174ab4dcbbfdfeea7727fb003,
title = "Methods for the Construction of Recombinant Oncolytic Myxoma Viruses",
abstract = "Myxoma virus (MYXV) has proven to be an effective candidate for oncolytic virotherapy in many preclinical cancer models. As a nonhuman pathogen, MYXV does not need to overcome any preexisting antiviral immunity, and its DNA cannot integrate into the host genome, making it an extremely safe vector. Moreover, the large dsDNA genome of MYXV allows the insertion of multiple transgenes and the design of engineered recombinant oncolytic viruses (OVs) with enhanced immunostimulatory or other desired properties. In this chapter, we describe detailed protocols for the generation and characterization of transgene-armed recombinant MYXV vectors.",
keywords = "Armed oncolytic virus, Engineered virus, Myxoma virus, Oncolytic virotherapy, Oncolytic virus, Poxvirus, Recombinant virus, Viral vector",
author = "Torres-Dom{\'i}nguez, {Lino E.} and {de Matos}, {Ana Lemos} and Rahman, {Masmudur M.} and Grant McFadden",
note = "Publisher Copyright: {\textcopyright} 2021, Springer Science+Business Media, LLC, part of Springer Nature.",
year = "2021",
doi = "10.1007/978-1-0716-1012-1_4",
language = "English (US)",
series = "Methods in Molecular Biology",
publisher = "Humana Press Inc.",
pages = "63--75",
booktitle = "Methods in Molecular Biology",
}